You are here: Industry Insights > AbbVie

News List

AbbVie Resolves HUMIRA® Patent Disputes with Amgen americanpharmaceuticacreview
September 30, 2017
AbbVie has announced a global resolution of all intellectual property-related litigation with Amgen over Amgen's proposed biosimilar adalimumab product.
Thanks to Amgen biosim settlement, AbbVie’s $20B Humira forecast looks real fiercepharma
September 29, 2017
AbbVie's assertion that Humira will sail clear for several years gained strength on Thursday as the drugmaker inked a patent settlement with Amgen, holding off that company's biosimilar until 2023.
AbbVie’s Maviret receives Japanese MHLW approval to treat HCV pharmaceufical-technology
September 29, 2017
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved AbbVie’s Maviret (glecaprevir / pibrentasvir) to treat adults with chronic hepatitis C virus (HCV) infection across genotypes 1 to 6 (GT1-6).
Five more biosimilar-free years for AbbVie’s Humira pharmafile
September 29, 2017
Humira is the key drug for AbbVie, and one the company hopes it will be able to push into the $20 billion region per year region before competition arrives.
AbbVie promises it's sticking with CEO's price-hike pledge, at least through 2018 fiercepharma
September 28, 2017
Facing heavy backlash over reports its executives considered dropping the company's pricing pledge, AbbVie maintained on Tuesday that it's sticking with the 10% price-hike limit for 2018.
What pledge? AbbVie executives may back off their vow to limit price hikes: report fiercepharma
September 26, 2017
Looking to combat the public drug-pricing backlash, AbbVie in January followed their peers in promising to hold the line at less than 10%.
AbbVie, Bristol-Myers Squibb Announce Clinical Research Collaboration americanpharmaceuticacreview
September 25, 2017
AbbVie is the sponsor conducting the trial. Specific terms of the agreement were not disclosed.
AbbVie and Bristol-Myers Squibb announce clinical research collaboration to evaluate a therapeutic r worldpharmanews
September 25, 2017
clinical trial collaboration to evaluate the combination of AbbVie's investigational antibody drug conjugate ABBV-399 and Bristol-Myers Squibb's immunotherapy Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer (NSCLC).
Roche and AbbVie's leukaemia combo smashes Phase 3 endpoint pharmafile
September 20, 2017
Venclexta/Venclyxto (venetoclax), Roche and AbbVie’s oral B-cell lymphoma-2 (BCL-2) inhibitor, successfully met its primary endpoint in Phase 3 trials
AbbVie preps JAK atopic dermatitis candidate for phase 3 fiercebiotech
September 11, 2017
GlobalData has predicted that new therapies will help boost the atopic dermatitis market from $3.6 billion in 2014 to $7.3 billion in 2024.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page